Granules India Limited

rs,

es India Limited. Table of Contents 1 Q3FY21 Highlights 2 Company Overview 3 Growth Drivers, Market Opportunities 4 Key Focus Areas in FY21 5 5-year Financial Highlights 6 Leadershi

20%

r Financial Highlights 6 Leadership Team 7 Sustainability Quarter at a Glance Revenue up 20% YoY, EBITDA margin expanded 190 bps YoY, followed by PAT growth of 129% YoY in Q3FY21 on back of ne

190 bps

adership Team 7 Sustainability Quarter at a Glance Revenue up 20% YoY, EBITDA margin expanded 190 bps YoY, followed by PAT growth of 129% YoY in Q3FY21 on back of new launches and better utilization o

129%

ter at a Glance Revenue up 20% YoY, EBITDA margin expanded 190 bps YoY, followed by PAT growth of 129% YoY in Q3FY21 on back of new launches and better utilization of Metformin block YoY ROE and ROCE

29%

21 on back of new launches and better utilization of Metformin block YoY ROE and ROCE improved to 29% and 32.4%, respectively Four new launches such as Ramelteon, Dexmethylphenidate HCI ER and Potassi

32.4%

ck of new launches and better utilization of Metformin block YoY ROE and ROCE improved to 29% and 32.4%, respectively Four new launches such as Ramelteon, Dexmethylphenidate HCI ER and Potassium Chlorid

INR 223

accretive products emphasize our core strength and backward integrated manufacturing. R&D spend at INR 223 Mn Received 2 ANDA approvals during the quarter Total 35 ANDA approvals from US FDA (34 Final appr

INR 4000

ditional capacity for PFIs. The facility will be operational in early FY24. The expected CAPEX is ~INR 4000 Mn, to be incurred over the next 3 years. 4 Granules India Limited. Q3FY21 vs. Q3FY20: Consolidat

rs. 4

e operational in early FY24. The expected CAPEX is ~INR 4000 Mn, to be incurred over the next 3 years. 4 Granules India Limited. Q3FY21 vs. Q3FY20: Consolidated Financial Highlights 1 Revenues Gross P

53.7%

Gross Profit and Gross Profit Margins EBITDA and EBITDA Margins (₹ Mn) 8,445 7,040 4,535 53.7% 3,569 50.7% 2,116 25.1% 1,632 23.2% Q3FY20 Q3FY21 Q3FY20 Q3FY21 Q3FY20 Q3FY21 PAT a

50.7%

and Gross Profit Margins EBITDA and EBITDA Margins (₹ Mn) 8,445 7,040 4,535 53.7% 3,569 50.7% 2,116 25.1% 1,632 23.2% Q3FY20 Q3FY21 Q3FY20 Q3FY21 Q3FY20 Q3FY21 PAT and PAT Margins

25.1%

t Margins EBITDA and EBITDA Margins (₹ Mn) 8,445 7,040 4,535 53.7% 3,569 50.7% 2,116 25.1% 1,632 23.2% Q3FY20 Q3FY21 Q3FY20 Q3FY21 Q3FY20 Q3FY21 PAT and PAT Margins Net Debt 1,46

“The facility will be operational in early FY24.”

“CAPEX: GIL has initiated an investment of 96 cr for an API facility which will be operational from Q3FY22.”

“The APIs from this block will be primarily used for integration into finished dosages.”

“• GIL will invest INR 2,400 Mn over FY21 to FY22; to be funded entirely via internal accruals • The products that will be manufactured in this block will be integrated with APIs from the Multi API block from Unit 5 in Vizag • The MUPS block will have a capacity to manufacture 2.5 – 5 Bn FDs per annum will be operational by Q3FY22 • Received approval for one product in FY21.”

“This product is under production in an existing facility and will be launched in Q1FY22.”

“The focus will be on strengthening the value proposition of existing molecules via integration by internal developments and strategic partnerships.”

No of APIs

3

As Encl

1

As Encl

Granules India Limited Investor Presentation December 2020 Safe harbor The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein. This presentation may include certain “forward looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially

No of APIs

28 Vertically Intergrated APIs 42% $20,217 Mn $26,288 Mn $48,257 Mn 28 13 7 3 15 15 8 5 8 Onco APIs Non-Onco APIs Total APIs FY20 FY21 FY22 Granules India Limited. Source: IQVIA MAT Aug 2020 20 New capacity expansion: MUPS technology What is MUPS technology? • Tablets, Capsules and other dosage forms which are prepared by compaction, encapsulation or blending of modified release coated pellets are based on MUPS (multi-unit pellet system) technology. • Pellets are produced for the purpose of oral controlled- release dosage form having gastro resistant or sustained- release properties • For such purposes, coated pellets are administered in the form of MUPS dosage forms. The coating material used is either sustained release or enteric release. • GIL will invest INR 2,400 Mn over FY21 to FY22; to be funded entirely via internal accruals • The products that will be manufactured in this block will be integrated with APIs from the Multi API block from Unit 5 in Vizag • The MUPS block will hav